Stock comparison
LeMaitre Vascular
Neurocrine Biosciences
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
LMAT
LeMaitre Vascular
Market cap
$2.23B
Sector
Healthcare
NBIX
Neurocrine Biosciences
Market cap
$15.76B
Sector
Healthcare
Overall winner
LeMaitre Vascular LMAT
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | LMAT | NBIX | Winner |
|---|---|---|---|
| Warren Buffett | 77B | 68B | LMAT |
| Benjamin Graham | 89A | 78B | LMAT |
| Philip Fisher | 81C | 80A | LMAT |
| Peter Lynch | 67B | 65B | LMAT |
| Joel Greenblatt | 56D | 55C | LMAT |
| Charlie Munger | 68D | 60C | LMAT |
| Terry Smith | 69D | 63D | LMAT |
Side-by-side metrics
| Metric | LMAT | NBIX |
|---|---|---|
| Market cap | $2.23B | $15.76B |
| P/E (TTM) | 37.1x | 22.6x |
| EV/EBIT | 36.6x | 24.7x |
| ROIC (TTM) | 9.43% | 13.68% |
| Gross margin | 72.39% | 98.17% |
| Net margin | 24.35% | 21.55% |
| Revenue CAGR 5y | 12.75% | 26.04% |
| EPS CAGR 5y | 19.04% | 50.0% |
| Debt / Equity | 0.5x | 0.1x |
| Dividend yield | 0.84% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
LMAT leads on
- Dividend yield0.84%vs 0.0%+100%
- Net margin24.35%vs 21.55%+11%
NBIX leads on
- Market cap$15.76Bvs $2.23B+86%
- Debt / Equity0.1xvs 0.5x+74%
- EPS CAGR 5y50.0%vs 19.04%+62%
- Revenue CAGR 5y26.04%vs 12.75%+51%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.